Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses

Xue Li; Vicki C. Tse; Wallis C. Y. Lau; Bernard M.Y. Cheung; Professor Gregory Lip; Ian Chi Kei Wong; Esther W. Chan

doi:10.1371/journal.pone.0157129

Related publications

Article2017

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

Xiaoyan Li, Steve Deitelzweig, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Professor Gregory Lip

Article2016

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Allison Keshishian, Shital Kamble, Xianying Pan, Jack Mardekian, Ruslan Horblyuk, Melissa Hamilton, Professor Gregory Lip

Article2016

Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

Iris Lin, Ruslan Horblyuk, Jack Mardekian, Sang Hee Park, Shital Kamble, Melissa Hamilton, Younos Abdulsattar, William Petkun, Joseph Menzin, Professor Gregory Lip

Article2018

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Professor Gregory Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak

Article2016

Abstract 19280: Real World Comparisons of Major Bleeding Risk Stratified by CHA2DS2-VASc Scores Among Non-Valvular Atrial Fibrillation Patients Initiating Apixaban or Warfarin

Professor Gregory Lip, Allison Keshishian, Shital Kamble, Xianying Pan, Jack Mardekian, Ruslan Horblyuk, Melissa Hamilton

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses

Abstract

Discussion(0)

Related publications

Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Abstract 19280: Real World Comparisons of Major Bleeding Risk Stratified by CHA2DS2-VASc Scores Among Non-Valvular Atrial Fibrillation Patients Initiating Apixaban or Warfarin